Wave Life Sciences' WVE-N531 Gains FDA Rare Pediatric Disease Status

The U.S. Food and Drug Administration (FDA) has given Wave Life Sciences, a biotechnology firm, Rare Paediatric Disease Designation for WVE-N531, an exon skipping oligonucleotide intended to stimulate the creation of endogenous, functional dystrophin protein. The medication is presently being assessed in the potentially registrational FORWARD-53 clinical study. Wave anticipates data delivery in the third quarter of 2024, including dystrophin protein expression from muscle biopsies following a 24-week course of therapy.

The FDA's designation highlights the substantial unmet needs related to Duchenne muscular dystrophy (DMD) and validates Wave's novel approach to medication development in the rare disease domain. The goal of WVE-N531 is to bring back functional, nearly full-length dystrophin protein at levels that are clinically significant. WVE-N531 achieved mean muscle tissue concentrations of ~42,000 ng/g (~6,100 nM) in a Part A study, which is approximately 20-30 times higher than levels reported by exon-skipping technologies leveraging muscle delivery conjugates in DMD patients. WVE-N531 also achieved industry-leading mean exon skipping levels of 53%.

ForWARD-53, a possibly registrational open-label clinical study including 11 boys with DMD, WAVE-N531 is presently being studied. Dystrophin expression during 24 and 48 weeks of therapy, together with information on pharmacokinetics, safety, and tolerability, are endpoints. Wave would be qualified to get a Priority Review Voucher in the event that the FDA approves the New Drug Application for WVE-N531.